48-Week End of Study Results from BEHOLD Phase 2 Study of UBX1325 in Patients with DME

Arshad M. Khanani, MD, MA, FASRS¹

Sharon Klier, MD, MPH², J. Rathmell, MA³, Lauren Masaki, BA², Tia Boonyapredee², Sara Huang, BSC², Mike Sapieha PhD^{2,4}, Jamie Dananberg, MD²

¹Sierra Eye Associates; Clinical Associate Professor, University of Nevada, Reno ²UNITY Biotechnology, South San Francisco, CA ³PharmaLex Corp ⁴University of Montreal

ASRS 30 July 2023 Late Breaking Session

Financial Disclosures

Consultant: AbbVie, Adverum, Aerie, Applied Genetics Technologies Corporation, Aldebaran, Allergan, Apellis, Arrowhead, Aviceda Therapeutics, Bausch + Lomb, Broadwing Bio, Clear side, 4D Molecular Therapeutics, Exgenesis, EyePoint, Frontera, Genentech, Inc., Gyroscope, iLumen, Iveric Bio, Janssen, Kato, Kartos, Kodiak Sciences, Kriya, Ocular Therapeutix, Oculis, OcuTerra, Olives Bio, Opthea, Oxurion, Nanoscope, Notal, Novartis, Perfuse, PolyPhotonix, Protagonist, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, Roche, RevOpsis, Stealth, Thea, <u>Unity Biotechnology</u>, Vanotech, Vial


Research Support: Adverum, Annexon, Apellis, 4D Molecular Therapeutics, Genentech, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Novartis, Ocular Therapeutix, Oculis, OcuTerra, Opthea, Oxurion, Oxular, Regenxbio, Rezolute, Roche, <u>Unity Biotechnology</u>.


Equity: Aviceda, Oculis, PolyPhotonix, Recens Medical, Retrotope, RevOpsis, Vial

What is Cellular Senescence and How Can it Lead to Disease?


Senescent cells are STRESSED, NO-LONGER DIVIDING, metabolically active cells that drive pathology:

- Accumulate in areas of disease activity
- Secrete inflammatory factors
- Do not form tight junctions with their neighboring healthy endothelial cells






UBX1325: a Bcl-xL Inhibitor, Selectively Eliminates Senescent Cells





Senescent (Sn) ECs accumulate in diabetic retinas in areas of disease activity - UBX1325 selectively triggers cell death of Sn ECs
- UBX1325 reduces retinal inflammation and vascular leakage

Preclinical data predicts progressive disease modification through vascular remodeling

UBX1325 Improves Retinal Vasculature in Mouse OIR Model







IVT UBX1325 decreases both neovascular and avascular areas in mouse OIR


UBX1325 Ph2 BEHOLD Study 48-Week Data in Patients with DME

BEHOLD Study Design, Patient Population, and Endpoints

Patient Population

Individuals with Diabetic Macular Edema

- Repeated anti-VEGF treatments (≥2 injections/6 months) Actual: 4.1 injections in prior 6 months
- Residual retinal fluid (≥300 µm) Actual: 439.6 µm
- Visual acuity deficit (73 ETDRS letters or worse) Actual: 61.4 ETDRS letters




Patient Characteristics at Baseline Were Well Balanced Between Groups

Parameter, Units (SD)	Sham	UBX1325
Age, Years	61.4 (9.09)	63.6 (9.33)
HBA1c, %	7.4 (1.36)	8.0 (1.68)
Diabetes Dx, Years	17.5 (10.53)	17.2 (11.41)
DME Dx, Years	3.0 (2.32)	3.5 (3.60)
BCVA, ETDRS letters	61.8 (9.61)	60.9 (9.97)
CST, µm	456.2 (98.07)	422.5 (84.16)
# anti-VEGF injections prior 190 days	4.1 (1.09)	4.1 (1.26)
Anti VEGF agent over prior 190 days (# of patients)		
Afilbercept	13	13
Aflibercept, bevacizumab	4	1
Bevacizumab	15	16
Ranibizumab	1	2

Balanced on other parameters at baseline: ethnicity & race, BMI, DRSS score

UBX1325-Treated Patients Had Marked Drop In Need For Anti-VEGF Rescue Beyond Week 18 Compared to Sham-Treated Patients Through 48 Weeks

- Median Time-To-First-Rescue in UBX arm was >48 weeks (at least 30 weeks greater than Sham arm)
- ~50% of UBX-treated patients went without rescue through 48 weeks
- ~80% of sham-treated patients required rescue before 48 weeks




Rescue Criteria (Either)


- Decrease of 10 ETDRS or more letters from any peak value
- Increase in CST of 75 µm or more from baseline

Efficacy analyses excluding and including data post anti-VEGF rescue show a treatment benefit of UBX1325

UBX1325-treated Patients Had a Significant Improvement in BCVA from Baseline[†] of 6.2 letters at 48 weeks (*excluding* data post-rescue)




CST Remained Stable In UBX1325-Treated Patients Compared to Worsening In Sham Patients (*Excluding* Post-Rescue Data)



NS: not significant

ASRS 2023

53.1% of UBX1325-Treated Patients In the Study Did Not Require Anti-VEGF Rescue Compared to 21.9% of Sham Patients at 48 Weeks




UBX1325 Demonstrated a Favorable Overall Safety and Tolerability Profile With **No Instances of Intraocular Inflammation, Endophthalmitis, Retinal Artery Occlusion or Vasculitis**

Parameter, No. of Patients	Sham (N = 33)	UBX1325 10 μg (N = 32)
Subjects with at least one TEAE	31 (93.9)	26 (81.3)
Related TEAE	3 (9.1)	6 (18.8)
Grade >=3 TEAE	4 (12.1)	5 (15.6)
Serious TEAE	3 (9.1)	5 (15.6)
Ocular TEAE for Study Eye	28 (84.8)	23 (71.9)
Treatment-related Ocular TEAE for Study Eye	3 (9.1)*	6 (18.8)*
TEAE leading to death	0	0
Intraocular inflammation, endophthalmitis, retinal artery occlusion, or vasculitis	0	0


 Most are likely procedural related, all were mild-mod, and self-limited: <u>Sham</u>: 1 conj. hemorrhage, 1 conj. hyperemia, 1 diabetic macular edema <u>UBX</u>: 5 conj. hemorrhage, 1 ant. chamber pigmentation, 1 eye irritation

Pre-specified Subgroup Analyses Higher BCVA Gain in UBX1325-Treated Patients With Baseline BCVA ≤60 Letters at 48 Weeks




ASRS 2023


Higher BCVA Gain in UBX1325-Treated Patients With Baseline CST > 400 at 48 Weeks



Trend Towards Higher BCVA Gain in UBX1325-Treated Patients With Baseline HBA1c \leq 7% at 48 Weeks



Trend Towards Higher BCVA Gain in UBX1325-Treated Patients With Baseline DRSS ≥47 at 48 Weeks



Conclusions

In the BEHOLD Phase Study, UBX1325:

 \bigtriangledown

Improved visual acuity at 48 weeks by 6.2 letters from baseline after a single injection



Led to ~50% of patients achieving a **rescue-free interval of at least 48 weeks** and may represent the **potential for disease modification**



Maintained retinal structure throughout the duration of the study without the need for anti-VEGF rescue



Had a generally favorable safety and tolerability profile with no intraocular inflammation